When it Comes to Medicines, Value is as Important as Cost11:30am-1:30pm | One King West Hotel - 1 King St. W. , Toronto
For some time now, discussions around access to life-saving medicines automatically include questions about how governments, private insurers and individual Canadians can afford them – and rightly so – but what about the value of investing in innovative medicines?
Despite representing only 6.4 per cent of the healthcare budget in Canada, innovative patented medicines have fundamentally changed the lives of patients suffering from acute or chronic illnesses. And in contrast to recent reports, prices for these medicines in Canada are well within those of other industrialized countries and on average are increasing at less than the rate of inflation.
Chris Halyk, President, Janssen Canada, will lead a discussion on the value, access and pricing of innovative medicines in Canada and will talk about the importance of collaboration to help ensure sustainable healthcare for Canadians.
Joining Chris Halyk in this dialogue:
• Mina Mawani, President and CEO, Crohn’s and Colitis Canada
• Sarah Beech, President, Accompass
• Perry Eisenschmid, CEO, Canadian Pharmacist’s Association
Individual seat: $89 +HST
Table (seats 10): $800 +HST
Individual seat: $110 +HST
Table (seats 10): $990 +HST
- Lunch will be served -
- For information about accessibility, please email firstname.lastname@example.org
- Dietary restriction notes and meal requests must be submitted to email@example.com 48 hours in advance of event.
President, Janssen Inc. Canada
Président, Janssen Inc. Canada
Chris Halyk was appointed President, Janssen Inc. in early 2006. Janssen is a brand name pharmaceutical company headquartered in Toronto, Canada and part of the Johnson & Johnson Family of Companies.
Mr. Halyk began his career with Johnson & Johnson when he joined Janssen Pharmaceutica Inc. in 1986 as an Over the Counter (OTC) product manager. Since then, Mr. Halyk held a number of sales and marketing roles of increasing responsibility including district sales manager, national sales director and, with the merger of Janssen Pharmaceutica and Ortho-McNeil in 1995, group product director, Gastrointestinal/Infectious Disease (GI/ID).
In 1997, Mr. Halyk was appointed Vice-President, Sales and Marketing and a member of the Janssen Management Board. His responsibilities included innovations in direct-to-consumer advertising, patient education programs and sales force automation.
In 2001, Mr. Halyk was appointed Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.
Before joining the company, Mr. Halyk worked for Warner-Lambert, a pharmaceutical company in Toronto.
Born and raised in Canada, Mr. Halyk holds an Honours Business Administration degree from the University of Western Ontario. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies from 2012 until 2013. He is married, has three children and lives in Oakville, Ontario.
- - - - -
Chris Halyk a été nommé au poste de président de Janssen Inc. au début de 2006. Janssen, un fabricant de médicaments de marque (dont le siège social est situé à Toronto, au Canada), est membre du Groupe des entreprises Johnson & Johnson.
M. Halyk a commencé sa carrière chez Johnson & Johnson en 1986, lorsqu’il s’est joint à Janssen Pharmaceutica Inc. en tant que chef de produits pour la catégorie des médicaments en vente libre. Depuis, M. Halyk a occupé divers postes de responsabilités croissantes en vente et en marketing, notamment, chef de district; directeur national des ventes; et, après la fusion de Janssen Pharmaceutica et d’Ortho-McNeil en 1995, directeur de groupe de produits, Maladies gastro-intestinales et infectieuses.
En 1997, M. Halyk a été nommé vice-président, Ventes et marketing, et membre du conseil de gestion de Janssen. Ses responsabilités comprenaient l’innovation publicitaire dirigée vers les consommateurs, les programmes d’éducation des patients et l’automatisation au sein de l’équipe de vente.
En 2001, M. Halyk a été nommé au poste de directeur général d’Ortho Biotech, la division biopharmaceutique de Janssen Inc.
Avant de se joindre à l’entreprise, M. Halyk avait travaillé chez Warner-Lambert, une entreprise pharmaceutique de Toronto.
M. Halyk est né et a grandi au Canada. Il possède un baccalauréat spécialisé en administration des affaires de l’Université de Western Ontario. Il a assumé la présidence du conseil d’administration pour Les compagnies de recherche pharmaceutique du Canada (Rx&D) de 2012 à 2013. Il est marié, a trois enfants, et réside à Oakville, en Ontario.
President & CEO
Crohn’s and Colitis Canada
Mina is a change navigator who leads nonprofits from vision to strategy to results. She has guided nonprofits towards improved capacity, stronger partnerships, better funding models and clearer vision for the future. Har Grover, Chair of the Board of Directors of Crohn’s and Colitis Canada, says, “The Board is extremely pleased to appoint Mina to this important role. Her passion and enthusiasm complement a strong track record in leadership positions in the not-for-profit sector and knowledge and experience in health science and administration.”
Mina brings to the role over 15 years of experience in nonprofit, private sector, hospital, and governmental roles. Recently, she has served as President and CEO of the Canadian Women’s Foundation, Chief Development Officer for CivicAction where she was a member of the Executive Committee, and as CEO of the Aga Khan Council for Canada.
Mina also serves as a Director for Women’s College Hospital and is a member of the International Women’s Forum Canada (IWFC) and serves on several IWFC Committees. Earlier in her career, she held key roles at the Ministry of Health and Long-Term Care, KPMG, and PricewaterhouseCoopers. Mina says, “Living with Crohn’s disease or ulcerative colitis can significantly impact one’s quality of life, and I have personally witnessed this in people who are very dear to me. Crohn’s and Colitis Canada’s promise and mission deeply resonate with me. I am honoured to lead this organization and I look forward to working with the board and staff, along with its stakeholders, to execute the mission and fulfill the promise of finding cures and improving the lives of children and adults living with these chronic diseases.”
Mina has earned a Masters in Health Science/Health Administration from the University of Toronto, a Bachelor of Administrative Studies from York University, and a diploma in Nuclear Medicine Technology from the Southern Alberta Institute of Technology.
Perry Eisenschmid, BBA, MBA, C.Dir., H.R.C.C.C.
Chief Executive Officer
Canadian Pharmacists Association
Perry Eisenschmid was appointed Chief Executive Officer of the Canadian Pharmacists Association (CPhA) in June 2013.
Perry has extensive experience in marketing financial services, consumer packaged goods and not-for-profit member services. His broad expertise includes marketing, sales and information technology with specific interest in strategy, branding, product management, web and social media innovation.
Perry obtained his BBA and MBA from the Schulich School of Business, York University. In 2010, he achieved certification as a Chartered Director (C.Dir.), and in 2013, he received Human Resources and Compensation Committee Certification (H.R.C.C.C.), both from the DeGroote School of Business, McMaster University.
Prior to joining CPhA, Perry was the Vice President of Marketing, Sales and IT with the Conference Board of Canada. He also had business responsibility for the organization’s multi-million dollar subscription and publications business and its web-based distribution channel. He was President and CEO of CIBC Trust and an executive for several years in CIBC’s Wealth Management Group.
Sarah J. Beech
Sarah Beech is the President of Accompass (formerly Pal Benefits), working out of the Toronto office. She is responsible for the overall management and operation of the firm.
Sarah has more than 27 years’ experience in the benefits industry. She began her career as an underwriter with a major Canadian insurance company, becoming the department supervisor within two years. She joined Hewitt Associates, a global human resources and outsourcing firm in 1990, where she eventually led the benefits consulting practice and, later, the entire Canadian consulting operation. She joined Accompass in 2012.
In her current role, Sarah creates and implements the firm’s business and marketing strategies, and builds, develops and manages new and existing client and third-party relationships.
Sarah is a member of the advisory board of Benefits Canada magazine and is frequent spokesperson and author on the topic of employee benefits. Sarah is a member of the Corporate Industry Council for Homeward Bound. She has a Bachelor of Arts degree from McGill University.